Compare TENX & ANTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TENX | ANTA |
|---|---|---|
| Founded | 1967 | 2022 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 68.2M |
| IPO Year | 2001 | 2024 |
| Metric | TENX | ANTA |
|---|---|---|
| Price | $1.48 | $2.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $10.29 | $8.25 |
| AVG Volume (30 Days) | ★ 1.4M | 16.2K |
| Earning Date | 11-05-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $38.46 |
| P/E Ratio | ★ N/A | $19.77 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $1.50 |
| 52 Week High | $19.40 | $10.60 |
| Indicator | TENX | ANTA |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 54.25 |
| Support Level | $1.34 | $2.12 |
| Resistance Level | $2.01 | $4.19 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 6.25 | 90.13 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.